+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Clinical Biomarkers Market: Focus on Product, Technology, End User, Clinical Area, Region and Competitive Landscape - Analysis and Forecast, 2019-2029

  • ID: 5013054
  • Report
  • March 2020
  • Region: Global
  • 213 Pages
  • BIS Research

Enquire about COVID-19 updates for this product.

Enquire Now
Global Clinical Biomarkers Market to Reach $45.91 Billion by 2029

FEATURED COMPANIES

  • Abbott Laboratories
  • ALCEDIAG
  • bioMérieux S.A.
  • CENTOGENE N.V.
  • Enzo Biochem Inc.
  • F. Hoffmann-La Roche Ltd.
  • MORE

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global clinical biomarkers market?
  • What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
  • What are the key technologies that have been used by leading players in the market for the development of biomarkers-based assays?
  • How each segment of the market is expected to grow during the forecast period from 2019 to 2029 based on:
    • Product type
    • Clinical area
    • Technology
    • End user
    • Region: Region includes North America, Europe, Asia-Pacific, Rest-of-the-World (ROW)
  • Who are the leading players with significant offerings to the global clinical biomarkers market? What is the expected market dominance for each of these leading players?
  • Which companies are anticipated to be highly disruptive in the future and why?

Global clinical biomarkers market analysis projects the market to grow at a significant CAGR of 10.07% during the forecast period, 2019-2029. Global clinical biomarkers market generated $16.01 billion in revenue in 2018, in terms of value.

The growth in the global clinical biomarkers market is anticipated to be driven by the increasing prevalence of infectious diseases, an increase in adoption of personalized medicine, growing focus on biomarker research and development programs and rising demand for non-invasive diagnosis. However, there are potential restraining factors hindering the growth of the market. These factors include uncertain reimbursement policies pertaining to clinical biomarkers-based products, requirement of high capital investment, and issues related to clinical validity of biomarkers.

Expert Quote

“Efficient translation of MS-based biomarker discovery research into the development of routine clinical diagnostic assays is an important challenge in the field of personalized medicine.”

Scope of the Market Intelligence on Global Clinical Biomarkers Market

Global clinical biomarkers market research provides a holistic view of the market in terms of various factors influencing it, including strategic developments and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with industrial and biological research. In addition, the study also includes exhaustive information on the unmet needs, perception of the new products, competitive landscape, market share of leading manufacturers, the growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global clinical biomarkers market.

Market Segmentation

  • Global clinical biomarkers market (on the basis of type) is segmented into diagnostic, prognostic and predictive biomarkers.
  • Global clinical biomarkers market (on the basis of clinical area) is segmented into cancer biomarkers, cardiac biomarkers, neurological biomarkers, infectious disease, immunological biomarkers, non-invasive prenatal testing, and other clinical areas.
  • Global clinical biomarkers market (on the basis of technology) is segmented into real-time polymerase chain reaction, next-generation sequencing, Enzyme-linked immunosorbent assay (ELISA), and other technologies.
  • Global clinical biomarkers market (on the basis of end user) is segmented into research and academic laboratories, diagnostic centers, biopharmaceutical, and biotech companies and other end users.

Key companies in the Global Clinical Biomarkers Market

The report also comprises 15 detailed company profiles including several key players, such as Abbott Laboratories, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc.,  Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Myriad Genetics, Hologic, Inc., Bio-Rad Laboratories, Inc.,  Qiagen N.V., Enzo Biochem Inc., Centogene N.V., ALCEDIAG, and Quest Diagnostics Incorporated.

Enterprise License customers will receive an Excel spreadsheet containing additional data.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • ALCEDIAG
  • bioMérieux S.A.
  • CENTOGENE N.V.
  • Enzo Biochem Inc.
  • F. Hoffmann-La Roche Ltd.
  • MORE

Executive Summary

1 Product Definition
1.1 Inclusion and Exclusion

2 Market Scope
2.1 Scope of Work
2.2 Key Questions Answered in the Report

3 Research Methodology
3.1 Global Clinical Biomarkers Market: Research Methodology
3.2 Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling

4 Market Overview
4.1 Introduction
4.2 Clinical Biomarkers Approaches in Precision Medicine
4.3 Market Available Clinical Biomarkers
4.4 Global Footprint

5 Global Clinical Biomarkers Market: Market Dynamics
5.1 Overview
5.2 Impact Analysis
5.3 Market Drivers
5.3.1 Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
5.3.2 Increase in Adoption of Personalized Medicine
5.3.3 Growing Focus on Biomarkers Research and Development Programs
5.3.4 Rising Demand for Non-Invasive Diagnosis
5.4 Market Restraints
5.4.1 Uncertain Reimbursement Policies Pertaining to Clinical Biomarkers
5.4.2 Requirement of High Capital Investment Hindering Expansion
5.4.3 Issues Related to Clinical Validity of Biomarkers-Based Tests
5.5 Market Opportunities
5.5.1 Massive Scope for Adoption of Clinical Biomarkers in Emerging Nations
5.5.2 Technological Advancements in Clinical Biomarkers-Based Tests
5.5.3 Increased Use of Clinical Biomarkers in Widespread Applications

6 Competitive Landscape
6.1 Key Strategies and Developments
6.1.1 Synergistic Activities
6.1.2 Product Approvals
6.1.3 Product Launches and Upgradations
6.1.4 Mergers and Acquisitions
6.1.5 Funding and Expansion
6.2 Market Share Analysis
6.3 Growth Share Analysis (Opportunity Mapping)
6.3.1 By Company

7 Global Clinical Biomarkers Market (by Type), 2018-2029
7.1 Diagnostic Biomarkers
7.2 Predictive Biomarkers
7.3 Prognostic Biomarkers

8 Global Clinical Biomarkers Market (by Clinical Area), 2018-2029
8.1 Cancer Biomarkers
8.1.1 Breast Cancer Biomarkers
8.1.2 Lung Cancer Biomarkers
8.1.3 Colorectal Cancer Biomarkers
8.1.4 Prostate Cancer Biomarkers
8.2 Cardiac Biomarkers
8.3 Neurological Biomarkers
8.4 Infectious Disease
8.5 Immunological Biomarkers
8.6 Non-Invasive Prenatal Testing
8.7 Other Clinical Areas

9 Global Clinical Biomarkers Market (by Technology), 2018-2029
9.1 Real-Time PCR
9.2 Enzyme-Linked Immuno Sorbent Assay (ELISA)
9.3 Immunohistochemistry (IHC)
9.4 Next-Generation Sequencing (NGS)
9.5 Other Technologies

10 Global Clinical Biomarkers Market (by End User), 2018-2029
10.1 Overview
10.2 Research and Academic Laboratories
10.3 Biopharmaceutical and Biotech Companies
10.4 Diagnostic Centers
10.5 Other End Users

11 Global Clinical Biomarkers Market (by Region), 2018-2029
11.1 Overview
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 U.K.
11.3.3 France
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 Australia
11.4.5 Singapore
11.4.6 Rest-of-APAC
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest-of-Latin America
11.6 Rest-of-the-World

12 Company Profiles
12.1 Overview
12.2 Abbott Laboratories
12.2.1 Company Overview
12.2.2 Role of Abbott Laboratories plc in the Global Clinical Biomarkers Market
12.2.3 Financials
12.2.4 Key Insights about Financial Health of the Company
12.2.5 SWOT Analysis
12.3 Agilent Technologies, Inc.
12.3.1 Company Overview
12.3.2 Role of Agilent Technologies, Inc. in the Global Clinical Biomarkers Market
12.3.3 Financials
12.3.4 Key Insights about Financial Health of the Company
12.3.5 SWOT Analysis
12.4 ALCEDIAG
12.4.1 Company Overview
12.4.2 Role of ALCEDIAG in Global Clinical Biomarkers Market
12.4.3 SWOT Analysis
12.5 Becton, Dickinson and Company
12.5.1 Company Overview
12.5.2 Role of Becton, Dickinson and Company in the Global Clinical Biomarkers Market
12.5.3 Financials
12.5.4 Key Insights about Financial Health of the Company
12.5.5 SWOT Analysis
12.6 bioMérieux S.A.
12.6.1 Company Overview
12.6.2 Role of bioMérieux S.A. in the Global Clinical Biomarkers Market
12.6.3 Financials
12.6.4 Key Insights about Financial Health of the Company
12.6.5 SWOT Analysis
12.7 Bio-Rad Laboratories, Inc.
12.7.1 Company Overview
12.7.2 Role of Bio-Rad Laboratories, Inc. in the Global Clinical Biomarkers Market
12.7.3 Financials
12.7.4 Key Insights about Financial Health of the Company
12.7.5 SWOT Analysis
12.8 CENTOGENE N.V.
12.8.1 Company Overview
12.8.2 Role of CENTOGENE N.V. in the Global Clinical Biomarkers Market
12.8.3 Financials
12.8.4 Key Insights about Financial Health of the Company
12.8.5 SWOT Analysis
12.9 F. Hoffmann-La Roche Ltd.
12.9.1 Company Overview
12.9.2 Role of F. Hoffmann-La Roche Ltd. in the Global Clinical Biomarkers Market
12.9.3 Financials
12.9.4 Key Insights about Financial Health of the Company
12.9.5 SWOT Analysis
12.10   Enzo Biochem Inc.
12.10.1 Company Overview
12.10.2 Role of Enzo Biochem Inc. in the Global Clinical Biomarkers Market
12.10.3 Financials
12.10.4 Key Insights about Financial Health of the Company
12.10.5 SWOT Analysis
12.11 Hologic, Inc.
12.11.1 Company Overview
12.11.2 Role of Hologic, Inc. in the Global Clinical Biomarkers Market
12.11.3 Financials
12.11.4 Key Insights about Financial Health of the Company
12.11.5 SWOT Analysis
12.12   Illumina, Inc.
12.12.1 Company Overview
12.12.2 Role of Illumina, Inc. in the Global Clinical Biomarkers Market
12.12.3 Financials
12.12.4 Key Insights about Financial Health of the Company
12.12.5 SWOT Analysis
12.13 Myriad Genetics, Inc.
12.13.1 Company Overview
12.13.2 Role of Myriad Genetics, Inc. in the Global Clinical Biomarkers Market
12.13.3 Financials
12.13.4 Key Insights about Financial Health of the Company
12.13.5 SWOT Analysis
12.14   Quest Diagnostics Incorporated
12.14.1 Company Overview
12.14.2 Role of Quest Diagnostics Incorporated in the Global Clinical Biomarkers Market
12.14.3 Financials
12.14.4 SWOT Analysis
12.15   QIAGEN N.V.
12.15.1 Company Overview
12.15.2 Role of QIAGEN N.V. plc in the Global Clinical Biomarkers Market
12.15.3 Financials
12.15.4 Key Insights about Financial Health of the Company
12.15.5 SWOT Analysis
12.16   Thermo Fisher Scientific Inc.
12.16.1 Company Overview
12.16.2 Role of Thermo Fisher Scientific in the Global Clinical Biomarkers Market
12.16.3 Financials
12.16.4 Key Insights about Financial Health of the Company
12.16.5 SWOT Analysis

List of Tables
Table 4.1: Key Commercialized Products Offered by Major Market Players
Table 5.1: Impact Analysis of Market Drivers
Table 5.2: Impact Analysis of Market Restraints
Table 8.1: Key Cancer Biomarkers Products Offered by Major Market Players
Table 8.2: Key Cancer Biomarkers Products Offered by Major Market Players
Table 8.3: Key Lung Cancer Biomarkers Products Offered by Major Market Players
Table 8.4: Key Colorectal Cancer Biomarkers Products Offered by Major Market Players
Table 8.5: Key Prostate Cancer Biomarkers Products Offered by Major Market Players
Table 8.6: Key Cardiac Biomarkers Products Offered by Major Market Players
Table 8.7: Key Neurological Biomarkers Products Offered by Major Market Players
Table 8.8: Key Infectious Disease Biomarkers Products Offered by Major Market Players
Table 8.9: Key Immunological Biomarkers Products Offered by Major Market Players
Table 8.10: Key Immunological Biomarkers Products Offered by Major Market Players
Table 8.11: Key Immunological Biomarkers Products Offered by Major Market Players
Table 9.1: Key RT-PCR-Based Biomarkers Products Offered by Major Market Players
Table 9.2: Key ELISA-Based Biomarkers Products Offered by Major Market Players
Table 9.3: Key IHC-Based Biomarkers Products Offered by Major Market Players
Table 9.4: Key NGS-Based Biomarkers Products Offered by Major Market Players
Table 9.5: Other Technologies-Based Biomarkers Products Offered by Major Market Players

List of Figures
Figure 1: Total Global Disease Burden by Cause, 2017
Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global Clinical Biomarkers Market
Figure 3: Share of Key Developments and Strategies, 2016-2019
Figure 4: Dominating Segments of the Global Clinical Biomarkers Market, 2019 and 2029
Figure 5: Global Clinical Biomarkers Market (by Product), 2019 and 2029
Figure 6: Global Clinical Biomarkers Market (by Clinical Area), 2019 and 2029
Figure 7: Global Clinical Biomarkers Market (by Technology), 2019 and 2029
Figure 8: Global Clinical Biomarkers Market (by End User), 2019 and 2029
Figure 9: Global Clinical Biomarkers Market (by Region), 2019 and 2029
Figure 2.1: Global Clinical Biomarkers Market Segmentation
Figure 3.1: Global Clinical Biomarkers Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Clinical Biomarkers Market, 2018 and 2029 ($Billion)
Figure 5.1: Number of Deaths by Top 18 Infectious Diseases, 2015
Figure 5.2: Number of Deaths (in Million) by Different Forms of Cancer, 2018
Figure 6.1: Share of Key Developments and Strategies, 2016–2019
Figure 6.2: Synergistic Activities Share (by Company), 2016 – 2019
Figure 6.3: Product Approval Share (by Company), 2016 –2019
Figure 6.4: Product Launches and Upgrades Share (by Company), 2016 –2019
Figure 6.5: Mergers and Acquisitions Share (by Company), 2016 –2019
Figure 6.6: Market Share Analysis for the Global Clinical Biomarkers Market, 2018
Figure 6.7: Growth Share Matrix for Global Clinical Biomarkers Market  (by Company), 2018
Figure 7.1: Global Clinical Biomarkers Market (by Type), 2018-2029 ($Billion)
Figure 7.2: Global Clinical Biomarkers Market for Diagnostic Biomarkers, 2018-2029 ($Billion)
Figure 7.3: Global Clinical Biomarkers Market for Predictive Biomarkers, 2018-2029 ($Billion)
Figure 7.4: Global Clinical Biomarkers for Prognostic Biomarkers, 2018-2029 ($Billion)
Figure 8.1: Global Clinical Biomarkers Market (by Clinical Area), 2018-2029 ($Billion)
Figure 8.2: Global Clinical Biomarkers Market for Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.3: Global Clinical Biomarkers Market for Breast Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.4: Global Clinical Biomarkers Market for Lung Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.5: Global Clinical Biomarkers Market for Colorectal Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.6: Global Clinical Biomarkers Market for Prostate Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.7: Global Clinical Biomarkers Market for Cardiac Biomarkers, 2018-2029 ($Billion)
Figure 8.8: Global Clinical Biomarkers Market for Neurological Biomarkers, 2018-2029 ($Billion)
Figure 8.9: Global Clinical Biomarkers Market for Infectious Disease Biomarkers, 2018-2029 ($Billion)
Figure 8.10: Global Clinical Biomarkers Market for Immunological Biomarkers, 2018-2029 ($Billion)
Figure 8.11: Global Clinical Biomarkers Market for Non-Invasive Prenatal Testing, 2018-2029 ($Billion)
Figure 8.12: Global Clinical Biomarkers Market for Other Clinical Areas, 2018-2029 ($Billion)
Figure 9.1: Global Clinical Biomarkers Market for Real Time PCR, 2018-2029 ($Billion)
Figure 9.2: Global Clinical Biomarkers Market for ELISA, 2018-2029 ($Billion)
Figure 9.3: Global Clinical Biomarkers Market for IHC, 2018-2029 ($Billion)
Figure 9.4: Global Clinical Biomarkers Market for NGS, 2018-2029 ($Billion)
Figure 9.5: Global Clinical Biomarkers Market for Other Technologies, 2018-2029 ($Billion)
Figure 10.1: Global Clinical Biomarkers Market (by End User)
Figure 10.2: Global Clinical Biomarkers Market (by End User), 2018-2029 ($Billion)
Figure 10.3: Global Clinical Biomarkers Market for Research and Academic Laboratories,  2018-2029 ($Billion)
Figure 10.4: Global Clinical Biomarkers Market for Biopharmaceutical and Biotech Companies, 2018-2029 ($Billion)
Figure 10.5: Global Clinical Biomarkers Market for Diagnostic Centres, 2018-2029 ($Billion)
Figure 10.6: Global Clinical Biomarkers Market for Other End Users, 2018-2029 ($Billion)
Figure 11.1: Global Clinical Biomarkers Market (by Region), 2019 and 2029 ($Billion)
Figure 11.2: Global Clinical Biomarkers Market (by Region), 2018-2029 ($Billion)
Figure 11.3: Global Clinical Biomarkers Market Share (by Region), 2018 ($Billion)
Figure 11.4: Global Clinical Biomarkers Market Share (by Region), 2029 ($Billion)
Figure 11.5: North America Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.6: North America Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
Figure 11.7: North America: Market Dynamics
Figure 11.8: The U.S. Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.9: Canada Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.10: Europe Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.11: Europe: Market Dynamics
Figure 11.12: Europe Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
Figure 11.13: Germany Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.14: U.K. Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.15: France Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.16: Italy Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11 17: Spain Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.18: Rest-of-Europe Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.19: Asia-Pacific Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.20: APAC: Market Dynamics
Figure 11.21: APAC Global Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
Figure 11.22: China Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.23: Japan Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.24: India Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.25: Australia Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.26: Singapore Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.27: Rest-of-Asia Pacific Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.28: Latin America Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.29: Latin America: Market Dynamics
Figure 11.30: Latin America Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
Figure 11.31: Brazil Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.32: Mexico Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.33: Rest-of-Latin America Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.34: RoW Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 12.1: Total Number of Companies Profiled
Figure 12.2: Abbott Laboratories: Overall Product Portfolio
Figure 12.3: Abbott Laboratories: Overall Financials, 2016-2018
Figure 12.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
Figure 12.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
Figure 12.6: Abbott Laboratories: Revenue (by Region), 2016-2018
Figure 12.7: Abbott Laboratories: R&D Expenditure, 2016-2018
Figure 12.8: Abbott Laboratories: SWOT Analysis
Figure 12.9: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 12.10: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 12.11: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 12.12: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.13: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 12.14: Agilent Technologies, Inc.: SWOT Analysis
Figure 12.15: ALCEDIAG: Overall Product Portfolio
Figure 12.16: ALCEDIAG: SWOT Analysis
Figure 12.17: Becton, Dickinson and Company: Overall Product Portfolio
Figure 12.18: Becton, Dickinson and Company: Overall Financials, 2017-2019
Figure 12.19: Becton, Dickinson and Company: Revenue (by Segment), 2017-2019
Figure 12.20: Becton, Dickinson and Company: Revenue (by Sub-Segment – BD Life Sciences), 2017-2019
Figure 12.21: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
Figure 12.22: Becton, Dickinson and Company: R&D Expenditure, 2017-2019
Figure 12.23: Becton, Dickinson and Company: SWOT Analysis
Figure 12.24: bioMérieux S.A.: Overall Product Portfolio
Figure 12.25: bioMérieux S.A.: Overall Financials, 2016-2018
Figure 12.26: bioMérieux S.A.: Revenue (by Segment), 2016-2018
Figure 12.27: bioMérieux S.A.: Revenue (by Region), 2016-2018
Figure 12.28: bioMérieux S.A.: R&D Expenditure, 2016-2018
Figure 12.29: bioMérieux S.A.: SWOT Analysis
Figure 12.30: Bio-Rad Laboratories, Inc: Overall Product Portfolio
Figure 12.31: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
Figure 12.32: Bio-Rad Laboratories, Inc.: Sales (by Segment), 2016-2018
Figure 12.33: Bio-Rad Laboratories, Inc.: Sales (by Region), 2016-2018
Figure 12.34: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 12.35: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 12.36: CENTOGENE N.V.: Overall Product Portfolio
Figure 12.37: CENTOGENE N.V.: Overall Financials, 2016-2018
Figure 12.38: CENTOGENE N.V.: Sales (by Segment), 2016-2018
Figure 12.39: CENTOGENE N.V.: Sales (by Region), 2016-2018
Figure 12.40: CENTOGENE N.V.: R&D Expenditure, 2016-2018
Figure 12.41: CENTOGENE N.V.: SWOT Analysis
Figure 12.42: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
Figure 12.43: F. Hoffmann-La Roche Ltd.: Overall Financials, 2016-2018
Figure 12.44: F. Hoffmann-La Roche Ltd.: Sales (by Segment), 2016-2018
Figure 12.45: F. Hoffmann-La Roche Ltd.: Sales (by Region), 2016-2018
Figure 12.46: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2016-2018
Figure 12.47: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 12.48: Enzo Biochem Inc.: Overall Product Portfolio
Figure 12.49: Enzo Biochem Inc.: Overall Financials, 2017-2019
Figure 12.50: Enzo Biochem Inc.: Revenue (by Segment), 2017-2019
Figure 12.51: Enzo Biochem Inc.: Revenue (by Region), 2017-2019
Figure 12.52: Enzo Biochem Inc.: R&D Expenditure, 2017-2019
Figure 12.53: Enzo Biochem Inc.: SWOT Analysis
Figure 12.54: Hologic, Inc.: Overall Product Portfolio
Figure 12.55: Hologic, Inc.: Overall Financials, 2017-2019
Figure 12.56: Hologic, Inc.: Sales (by Segment), 2017-2019
Figure 12.57: Hologic, Inc.: Sales (by Region), 2017-2019
Figure 12.58: Hologic, Inc.: R&D Expenditure, 2017-2019
Figure 12.59: Hamilton, Inc.: SWOT Analysis
Figure 12.60: Illumina, Inc: Overall Product Portfolio
Figure 12.61: Illumina, Inc.: Overall Financials, 2016-2018
Figure 12.62: Illumina, Inc.: Sales (by Segment), 2016-2018
Figure 12.63: Illumina, Inc.: Sales (by Region), 2016-2018
Figure 12.64: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 12.65: Illumina, Inc.: SWOT Analysis
Figure 12.66: Myriad Genetics, Inc.: Overall Product Portfolio
Figure 12.67: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 12.68: Myriad Genetics, Inc.: Sales (by Segment), 2017-2019
Figure 12.69: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 12.70: Myriad Genetics, Inc.: SWOT Analysis
Figure 12.71: Quest Diagnostics Incorporated, Inc.: Overall Product Portfolio
Figure 12.72: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
Figure 12.73: Quest Diagnostics Incorporated.: Sales (by Segment), 2016-2018
Figure 12.74: Quest Diagnostics Incorporated: SWOT Analysis
Figure 12.75: QIAGEN N.V.: Overall Product Portfolio
Figure 12.76: QIAGEN N.V.: Overall Financials, 2016-2018
Figure 12.77: QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 12.78: QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 12.79: QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 12.80: QIAGEN N.V.: SWOT Analysis
Figure 12.81: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 12.82: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
Figure 12.83: Thermo Fisher Scientific Inc: Sales (by Segment), 2016-2018
Figure 12.84: Thermo Fisher Scientific Inc.: Sales (by Region), 2016-2018
Figure 12.85: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
Figure 12.86: Thermo Fisher Scientific Inc.: SWOT Analysis

Note: Product cover images may vary from those shown

Loading
LOADING...

FEATURED COMPANIES

  • Abbott Laboratories
  • ALCEDIAG
  • bioMérieux S.A.
  • CENTOGENE N.V.
  • Enzo Biochem Inc.
  • F. Hoffmann-La Roche Ltd.
  • MORE

According to the market intelligence report titled “Global Clinical Biomarkers Market- Analysis and Forecast, 2019-2029”, the global clinical biomarkers market was valued at $16.01 billion in 2018 and is anticipated to grow over $45.91 billion by 2029. The global clinical biomarkers market is expected to grow at a double-digit compound annual growth rate in the forecast period 2019-2029, aided primarily by the impressive growth in the underlying manufacturing market.

A clinical biomarker refers to the biological parameter which is evaluated or measured as an indicator of any pathogenic or pharmacologic or a therapeutic intervention response. Clinical biomarkers play a significant role in the diagnosis, prognosis, and treatment of a disease. In the recent past, there has been considerable activity in the development of biomarkers for the diagnosis and prognosis of common diseases such as infectious disease, heart disease, and cancer, offering early detection of these diseases. The advent of precision medicine and the increased awareness of the enhanced quality of life among the physicians and patients has facilitated the development of molecular biomarkers for effective decision making and accurate predictions. The clinical application of the biomarkers in the drug discovery and disease diagnosis has filled the gap between the diagnostic approaches and the lack of tools for the effective evaluation and treatment.

“North America is the leading contributor in the global clinical biomarkers market and contributed approximately 42.33% to the market value in 2018. This segment is anticipated to grow at a CAGR of 9.69% during the forecast period 2019-2029 and continue dominating the global market in 2029 as well. However, Asia-Pacific is expected to grow at an impressive CAGR of 10.49% during the forecast period from 2019-2029. The growth is mainly due to the increasing adoption of personalized medicine and the piqued interest of the biopharmaceutical companies in the development of the product based on clinical biomarkers.

Research Highlights:

  • Cancer biomarkers are the leading contributor in the global clinical biomarkers market and contributed approximately 55.40% in the 2018 market value. However, the global clinical biomarker for neurological biomarkers is anticipated to witness the fastest growth at the CAGR of 10.32% during the forecast period 2019-2029.
  • F. Hoffmann-La Roche AG is currently the largest shareholder with a share of 22.59% in the global clinical biomarkers market. This market dominance is attributed to the company’s presence within the market through its expansive product portfolio, led by dedicated products.

This market intelligence report provides a multi-dimensional view of the global clinical biomarkers market in terms of market size and growth potential. This research report aims at answering various aspects of the global clinical biomarkers market with the help of key factors driving the market, restraints that can possibly inhibit the overall growth of the market, and the current growth opportunities that are going to shape the future trajectory of the market expansion.
 
Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches and approvals, partnerships, collaborations, business expansions, as well as mergers and acquisitions, among others. The research report provides a comprehensive analysis of the product sales, manufacturers, service providers, and trend analysis by segment, and growth share analysis by geographical region. Additionally, the report provides a comprehensive attractive analysis and opportunity analysis for the entire global clinical biomarkers market for 2019 and 2029.

This report is a meticulous compilation of research on more than 30 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The report also comprises 15 detailed company profiles including several key players, such as Abbott Laboratories, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc.,  Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Myriad Genetics, Hologic, Inc., Bio-Rad Laboratories, Inc.,  Qiagen N.V., Enzo Biochem Inc., Centogene N.V., ALCEDIAG, and Quest Diagnostics Incorporated.

Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ALCEDIAG
  • Becton, Dickinson and Company
  • bioMérieux S.A.
  • Bio-Rad Laboratories, Inc.
  • CENTOGENE N.V.
  • F. Hoffmann-La Roche Ltd.
  • Enzo Biochem Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Quest Diagnostics Incorporated
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown
Adroll
adroll